Bull and Bear

Bull and Bear

Verdict: Lean Long, Wait For Confirmation — the margin-recovery evidence is real but early. Q1 2026's $3.37 adjusted EPS demonstrated genuine operational improvement in Medicaid HBR (93.1% vs. 93.6% YoY), the stock trades at a generational valuation discount (0.13x revenue, 16x guided earnings), and the D-SNP structural tailwind is unpriced. But the recovery is one quarter old, management credibility was severely damaged by FY2025's 65% guidance miss, and the OBBBA's Medicaid work requirements create a visible headwind to membership composition starting 2027. The tension that matters most: whether Q1 2026's HBR improvement reflects durable trend management or a favorable flu season that flatters the early data. Q2–Q3 2026 HBR progression and the June Wakely risk adjustment data will decide it.

Bull Case

Bull's price target: $85, based on normalized adj EPS of $5.50 (mid-recovery, not full normalization) × 15.5x P/E (below 15-year median, reflecting ongoing policy risk). Timeline: 12–18 months. Primary catalyst: Q2–Q3 2026 HBR progression confirming sustained Medicaid margin improvement, plus June Wakely data confirming Marketplace risk adjustment receivable. The disconfirming signal: Medicaid HBR fails to improve below 93.5% by Q3 2026, or Marketplace risk adjustment comes in as a payable.

Bear Case

Bear's downside target: $30, based on trough adj EPS of $2.50 (H2 2026 HBR reversal) × 12x P/E (distressed government-contractor multiple). Timeline: 6–12 months. Primary trigger: Q2 2026 Medicaid HBR fails to improve or deteriorates, and June Wakely data shows Marketplace risk adjustment payable. The cover signal: two consecutive quarters of Medicaid HBR improvement below 93% combined with confirmed Marketplace risk adjustment receivable.

The Real Debate

Verdict

Verdict: Lean Long, Wait For Confirmation. The Bull carries more weight because the valuation discount is extreme and objectively measurable (0.13x revenue is half the nearest peer), the Q1 2026 earnings beat was driven by operational metrics rather than accounting, and the D-SNP mandate provides a structural growth driver the market is not pricing. The most important tension is whether Q1's HBR improvement is seasonal or structural — this single variable controls whether adj EPS normalizes to $5–6 (Bull's thesis) or stalls at $2–3 (Bear's thesis). The Bear could still be right: if behavioral health costs re-accelerate in H2 2026 and the OBBBA strips healthy Medicaid members from the pool, the margin recovery stalls and the stock revisits $30–35. The condition that would change this verdict from "Lean Long" to a firm conviction call: two consecutive quarters of Medicaid HBR improvement (Q2 and Q3 2026 both below 93%) combined with confirmed Marketplace risk adjustment receivable from June Wakely data. Until those data points arrive, the position requires patience and a willingness to accept interim volatility.